argenx SE (ARGX.BR)
73.30EUR
4:35pm BST
€-0.20 (-0.27%)
€73.50
€73.10
€73.50
€71.10
78,725
97,018
€94.80
€18.90
About
Overall
| Beta: | -- |
| Market Cap(Mil.): | €583.54 |
| Shares Outstanding(Mil.): | 26.89 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| ARGX.BR | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 85.68 | 33.65 |
| EPS (TTM): | -1.07 | -- | -- |
| ROI: | -19.69 | 0.45 | 14.28 |
| ROE: | -19.69 | 1.37 | 16.00 |
AbbVie doubles down on cancer project with biotech group Argenx
BRUSSELS Biotech group Argenx said on Wednesday U.S. pharma group AbbVie had exercised an exclusive option to develop and commercialize one of its experimental drugs which could lead to payments of up to $625 million.
AbbVie doubles down on cancer project with biotech group Argenx
BRUSSELS Biotech group Argenx said on Wednesday U.S. pharma group AbbVie had exercised an exclusive option to develop and commercialise one of its experimental drugs which could lead to payments of up to $625 million(490.08 million pounds).
AbbVie doubles down on cancer project with biotech group Argenx
BRUSSELS, Aug 22 Biotech group Argenx said on Wednesday U.S. pharma group AbbVie had exercised an exclusive option to develop and commercialise one of its experimental drugs which could lead to payments of up to $625 million.
BRIEF-Argenx: Publication Of Study Results From Phase 1 Of FcRn-Antagonist Efgartigimod
* ANNOUNCED ON TUESDAY PUBLICATION OF FULL STUDY RESULTS FROM PHASE 1 OF FCRN-ANTAGONIST EFGARTIGIMOD (ARGX-113) IN HEALTHY VOLUNTEERS
BRIEF-Argenx Q1 Operating Income Down At 6.9 Million Euros
* ARGENX REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
BRIEF-Argenx To Present Complete Data From Phase 2 Proof-Of-Concept Trial Of Efgartigimod (Argx-113)
* REG-ARGENX TO PRESENT COMPLETE DATA FROM PHASE 2 PROOF-OF-CONCEPT TRIAL OF EFGARTIGIMOD (ARGX-113) IN GENERALIZED MYASTHENIA GRAVIS AT AMERICAN ACADEMY OF NEUROLOGY (AAN) ANNUAL MEETING
Estimates